RZLT
HEALTHCARERezolute Inc
$3.14-0.15 (-4.56%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving RZLT Today?
No stock-specific AI insight has been generated for RZLT yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.07$11.46
$3.14
Fundamentals
Market Cap$300M
P/E Ratio—
EPS$-0.93
Dividend Yield—
Dividend / Share—
ROE-0.7%
Profit Margin—
Debt / Equity—
Trading
Volume1.6M
Avg Volume (10D)—
Shares Outstanding95.7M
RZLT News
21 articles- Rezolute Announces Oral Presentation of Results From its Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism at the Pediatric Endocrine Society Annual MeetingYahoo Finance·May 1, 2026
- Rezolute, Inc. Investigated by the Portnoy Law FirmGlobeNewswire Inc.·Apr 24, 2026
- Rezolute to Present Results from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism at the Pediatric Endocrine Society (PES) Annual MeetingYahoo Finance·Apr 21, 2026
- Stock Market Today, April 6: Soleno Therapeutics Climbs After $2.9 Billion All-Cash Buyout AgreementMotley Fool·Apr 6, 2026
- Rezolute Stock Gains After FDA Meeting on Ersodetug Program UpdateYahoo Finance·Mar 25, 2026
- Rezolute Provides Update on its Congenital Hyperinsulinism Program Following FDA MeetingYahoo Finance·Mar 24, 2026
- XOMA Royalty Q4 Earnings Call HighlightsMarketbeat·Mar 18, 2026
- Rezolute to Participate in the Citizens Life Sciences ConferenceYahoo Finance·Mar 4, 2026
- Rezolute Reports Second Quarter Fiscal 2026 Financial Results and Provides Business UpdateYahoo Finance·Feb 12, 2026
- Rezolute to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026Yahoo Finance·Feb 4, 2026
- Rezolute Provides Insights from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism and Shares Findings from its Expanded Access Program in Tumor HyperinsulinismYahoo Finance·Jan 7, 2026
- Rezolute’s Phase 3 sunRIZE Study for Ersodetug Fails to Meet Primary and Secondary Endpoints Despite Analyst BackingYahoo Finance·Dec 31, 2025
- Insiders Made Their Bets in 2025—These Were the Top 5 Stocks They BoughtInsidertrades·Dec 30, 2025
- Chief Financial Officer of Rezolute Daron Evans Buys 21% More SharesYahoo Finance·Dec 18, 2025
- RZLT Stock Plummets 79% Month to Date: Here's What You Need to KnowYahoo Finance·Dec 17, 2025
- Down 81.8% in 4 Weeks, Here's Why Rezolute (RZLT) Looks Ripe for a TurnaroundYahoo Finance·Dec 15, 2025
- Rezolute (RZLT) Is Down 82.7% After Phase 3 sunRIZE Failure in Congenital Hyperinsulinism TrialYahoo Finance·Dec 15, 2025
- Rezolute stock crashes after sole pipeline candidate fails Phase IIIClinicaltrialsarena·Dec 12, 2025
- Praxis tees up another approval filing; Geron turns to layoffsBiopharmadive·Dec 12, 2025
- Xoma Crumbles And Partner Rezolute Collapses On Failed Insulin Disease DrugYahoo Finance·Dec 11, 2025
- Rezolute (RZLT): Assessing Valuation After a Year of Strong Share Price GainsYahoo Finance·Dec 11, 2025
All 21 articles loaded
Price Data
Open$0.00
Previous Close$3.29
Day High$0.00
Day Low$0.00
52 Week High$11.46
52 Week Low$1.07
52-Week Range
$1.07$11.46
$3.14
Fundamentals
Market Cap$300M
P/E Ratio—
EPS$-0.93
Dividend Yield—
Dividend / Share—
ROE-0.7%
Profit Margin—
Debt / Equity—
Trading
Volume1.6M
Avg Volume (10D)—
Shares Outstanding95.7M
About Rezolute Inc
Rezolute, Inc., a clinical-stage biopharmaceutical company, develops rare and metabolic disease therapies in the United States. The company is headquartered in Redwood City, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—